Q-omics provides the consensus-scored CCDC39 profile across patient tissues and cancer cell-line models. CCDC39 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC39 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CCDC39 RNA expression shows 20,463 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where CCDC39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC39 survival associations across molecular data types. CCDC39 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC39 RNA expression–survival associations across cancer types. High CCDC39 expression shows unfavorable associations in KIRC, LGG and KICH, but favorable associations in HNSC, READ and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC39 RNA expression.
This table summarizes CCDC39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC39 shows lower tumor expression in THCA, LUSC, LUAD, KICH and UCEC and higher tumor expression in LIHC. The THCA box plot shows higher CCDC39 RNA expression in normal versus tumor tissue (log2 FC = −0.860, t-test p < 0.001).
This table shows molecular features associated with CCDC39 in patient tissues and cancer cell lines. In patient samples, CCDC39 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
